Vol 6 Issue 6

Immuno-oncology: manufacturing and commercial business models for the new decade

Jul 2020

Guest Editor:

Usman Azam, President & CEO at Tmunity Therapeutics Inc

Foreword

Immuno-oncology: manufacturing and commercial business models for the new decade – Foreword

Usman Azam

28 July 2020

Foreword

Expert Insight

Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors

Maria Fardis,

Kelly DiTrapani,

Friedrich Graf Finckenstein,

Cécile Chartier

3 July 2020

Expert Insight

Innovating CAR T cell therapy for today and tomorrow

David Chang

30 June 2020

Expert Insight

Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Glen Firestone

30 June 2020

Expert Insight

Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies

Matthew Li,

Sadik Kassim

18 June 2020

Expert Insight

Commercialization of TCR T-cell therapy: patient journey implications

Kimberly Freeman

17 June 2020

Expert Insight

Innovator Insight

Simplifying GMP CART and CAR NK cell therapy manufacturing processes

Sarah Dluczek,

Kate Fynes,

Stephan Fricke,

Ulrike Koehl,

Martha Luevano,

Xiuyan Wang

16 July 2020

Innovator Insight

Interview

Looking to the future of stem cell-derived immunotherapy

Peter Zandstra

17 June 2020

Interview

Understanding the drivers of success and failure in CAR T cell therapy

Jan Melenhorst

16 June 2020

Interview

Expert Roundtable Video

Expert Roundtable: evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Derek Adams,

Greg Russotti,

John Lunger,

Evonne Fearnot,

Emilie Gauthy

17 July 2020

Expert Roundtable Video

Watch now

Expert Roundtable

Evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Derek Adams,

Greg Russotti,

John Lunger,

Evonne Fearnot,

Emilie Gauthy

16 July 2020

Expert Roundtable

Vector characterization and validation

Interview

Priorities for AAV vector analytics development

Christine Le Bec

30 July 2020

Interview

Commercial Insight May 2020

Commercial Insights

Cell & Gene Therapy Commercial Insight - May 2020

Mark Curtis,

Richard Philipson

24 June 2020

Commercial Insights

Clinical Trends July 2020

Commentary

Clinical trials in the era of Covid-19: successes, failures & ongoing challenges

Sven Kili

4 August 2020

Commentary

Interview

Innovation in clinical translation of advanced therapies

Mohamed Abou El-Enein

7 August 2020

Interview

Preliminary Communication

A proposed protocol of derived mesenchymal stem cells for the treatment of COVID-19 patients

Vasiliki Kalodimou,

Alma Reyes-Calavera

10 July 2020

Preliminary Communication

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

Martha Luevano, Global Product Manager at Miltenyi Biotec

Xiuyan Wang, Assistant Director, Michael G. Harris Cell Therapy & Cell Engineering Facility at Memorial Sloan-Kettering Cancer Center

Stephan Fricke, Head of GMP Process Development at Fraunhofer Institute for Cell Therapy & Immunology IZI

Sarah Dluczek, Technical Leader, GMP Unit at Fraunhofer Institute for Cell Therapy & Immunology IZI

Kate Fynes, Process Development Investigator, Cell & Gene Therapy CMC at GlaxoSmithKline

Ulrike Koehl, Director & Head, Institute of Cell Therapeutics & GMP Development Unit at Hannover Medical School

9 June 2020

Webinar

Watch now

Challenges of cell collections for cell therapy manufacturing: what do we want in the bag?

Elizabeth Valdez, RN & MSN Global Trainer at Terumo BCT

Jim Beltzer, Global Strategy Lead, Cell Therapy

Sandeep Soni, Associate Professor, Pediatric Stem Cell Transplant, Gene Therapy & Regenerative Medicine at Stanford University School of Medicine

Melinda Caltabiano, Director, Apheresis Operations at Dendreon Pharmaceuticals

Krishnendu Roy, Professor, Director, Marcus Center for Therapeutic Cell Characterization & Manufacturing (MC3M) at Georgia Institute of Technology

24 June 2020

Webinar

Watch now

Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

Ali Mohamed, Vice President, CMC at Immatics

Megan Ciarlo, Technology & Applications Specialist at Miltenyi Biotec

14 July 2020

Webinar

Watch now

Identifying the critical factors for commercial-scale viral vector process development and manufacturing

Behnam Baghbaderani, Global Head, Process Development, Emerging Technologies at Lonza Pharma & Biotech

Xin Swanson, Head, Business Development, Viral-based Therapeutics at Lonza Pharma & Biotech

Suparna Sanyal, Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec

26 August 2020

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Jul 2020. Vol 6 Issue 6

FEATURING

Spotlight

Immuno-oncology: manufacturing and commercial business models for the new decade

Sponsors

Foreword

Immuno-oncology: manufacturing and commercial business models for the new decade – Foreword

Expert Insight

Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors

Innovating CAR T cell therapy for today and tomorrow

Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies

Commercialization of TCR T-cell therapy: patient journey implications

Innovator Insight

Simplifying GMP CART and CAR NK cell therapy manufacturing processes

Interview

Looking to the future of stem cell-derived immunotherapy

Understanding the drivers of success and failure in CAR T cell therapy

Expert Roundtable Video

Expert Roundtable: evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Expert Roundtable

Evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Vectors FOCUS

Vector characterization and validation

Interview

Priorities for AAV vector analytics development

Report

Commercial Insight May 2020

Commercial Insights

Cell & Gene Therapy Commercial Insight - May 2020

Report

Clinical Trends July 2020

Commentary

Clinical trials in the era of Covid-19: successes, failures & ongoing challenges

Interview

Innovation in clinical translation of advanced therapies

Other articles

Preliminary Communication

A proposed protocol of derived mesenchymal stem cells for the treatment of COVID-19 patients

Webinars

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

Challenges of cell collections for cell therapy manufacturing: what do we want in the bag?

Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

Identifying the critical factors for commercial-scale viral vector process development and manufacturing